A tighter archive for life-science signals.
Search once, then narrow by source or topic.
Lonza’s Stock In Recovery Mode: Is This Swiss CDMO Finally Back On Track? - AD HOC NEWS
Lonza’s Stock In Recovery Mode: Is This Swiss CDMO Finally Back On Track? - AD HOC NEWS
Lonza’s Stock In Recovery Mode: Is This Swiss CDMO Finally Back On Track? - AD HOC NEWS
Lonza’s Stock In Recovery Mode: Is This Swiss CDMO Finally Back On Track? - AD HOC NEWS
Lonza Refreshes Board with Technology-Focused Appointments in Governance Overhaul - TipRanks
Lonza Refreshes Board with Technology-Focused Appointments in Governance Overhaul - TipRanks
Lonza Group (OTCMKTS:LZAGY) Stock Rating Upgraded by Royal Bank Of Canada - MarketBeat
Lonza Group (OTCMKTS:LZAGY) Stock Rating Upgraded by Royal Bank Of Canada - MarketBeat
RBC upgrades Lonza Group AG (LZAGY) to Outperform Feb 2026 - Meyka
RBC upgrades Lonza Group AG (LZAGY) to Outperform Feb 2026 - Meyka
Lonza Group (OTCMKTS:LZAGY) Sees Unusually-High Trading Volume - Time to Buy? - MarketBeat
Lonza Group (OTCMKTS:LZAGY) Sees Unusually-High Trading Volume - Time to Buy? - MarketBeat
Speed-to-IND Starts with Toxicology: A Rapid-Fire Q&A with Lonza - BioPharm International
Speed-to-IND Starts with Toxicology: A Rapid-Fire Q&A with Lonza - BioPharm International
Lonza’s Strategic Pivot Fuels Robust Growth and Shareholder Returns - AD HOC NEWS
Lonza’s Strategic Pivot Fuels Robust Growth and Shareholder Returns - AD HOC NEWS
Lonza Issues Partially Unreadable Release, Leaving Details Unclear - TipRanks
Lonza Issues Partially Unreadable Release, Leaving Details Unclear - TipRanks
Lonza Group (OTCMKTS:LZAGY) Rating Lowered to "Strong Sell" at Zacks Research - MarketBeat
Lonza Group (OTCMKTS:LZAGY) Rating Lowered to "Strong Sell" at Zacks Research - MarketBeat
2026 Outlook: CDMO Market for Injectables - DCAT Value Chain Insights
2026 Outlook: CDMO Market for Injectables - DCAT Value Chain Insights
Lonza Group Ltd (LONN) Gets a Buy from UBS - The Globe and Mail
Lonza Group Ltd (LONN) Gets a Buy from UBS - The Globe and Mail
Barclays Reaffirms Their Buy Rating on Lonza Group Ltd (LONN) - The Globe and Mail
Barclays Reaffirms Their Buy Rating on Lonza Group Ltd (LONN) - The Globe and Mail
Barclays Reaffirms Their Buy Rating on Lonza Group Ltd (LONN) - The Globe and Mail
Barclays Reaffirms Their Buy Rating on Lonza Group Ltd (LONN) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Idexx Laboratories (IDXX) and Lonza Group (OtherLZAGY) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Idexx Laboratories (IDXX) and Lonza Group (OtherLZAGY) - The Globe and Mail
45% earnings growth over 1 year has not materialized into gains for Lonza Group (VTX:LONN) shareholders over that period - Yahoo Finance
45% earnings growth over 1 year has not materialized into gains for Lonza Group (VTX:LONN) shareholders over that period - Yahoo Finance
Earnings call transcript: Lonza misses Q4 2025 forecasts, stock drops 9% - Investing.com
Earnings call transcript: Lonza misses Q4 2025 forecasts, stock drops 9% - Investing.com
Deutsche Bank Maintains Buy on Lonza Group AG (LZAGY) Feb 2026 - Meyka
Deutsche Bank Maintains Buy on Lonza Group AG (LZAGY) Feb 2026 - Meyka
Brand directory, kept in view
A rolling strip of the companies, platforms, CROs and device makers that show up across the coverage.
Open about page